Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) to Present at NobleCon17

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading producer of uranium and critical minerals in the United States, is pleased to announce that the company’s president and CEO Mark S. Chalmers will present at NobleCon17 – Noble Capital Markets’ Seventeenth Annual Investor Conference on Tuesday, Jan. 19, 2021 at 10:30 a.m. ET. According to the update, the conference is virtual, with no cost, obligation or restrictions to attend. Chalmers will provide an update on Energy Fuels’ various uranium and critical mineral initiatives, with particular emphasis on the company’s progress on producing rare earth elements. A high-definition, video webcast of the presentation will be available the following day on the company’s website and as a part of a complete catalog of presentations to be rebroadcast on Channelcheck next month.

To view the full press release, visit https://ibn.fm/C3kIp

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and anticipates commencing commercial production of rare earth element (“REE”) carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, has the ability to produce vanadium when market conditions warrant and is completing final test-work for the production of REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU 

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Energy Fuels Inc. UUUU, MissionIRNewsBreaks | Leave a comment

Autonomous Security Robots Showcase Knightscope, Inc.’s Focus on Market Logical Use of Self-Driving Tech

  • Amid increasing concerns about personnel security from criminal elements, autonomous security robot maker Knightscope is advancing efforts to help make America the safest country in the world
  • Knightscope’s AI-enhanced robot sentries have been deployed to Fortune 1000 companies, hospitals, police departments, municipalities, utilities and casinos
  • The company’s models include stationary robots as well as mobile products that patrol indoor and outdoor locations
  • The robots use artificial intelligence and feature 360-degree eye-level HD streaming video, autonomous recharging, face and license plate recognition, and infrared thermal detection to deter crime and transmit safety or investigational information
  • The sentries have the added benefit of being unaffected by the infectious contagion hampering the performance of many employees while the COVID pandemic remains in effect

Autonomous robot manufacturer Knightscope aims to make the United States the safest country on earth with the help of its artificial intelligence-enhanced machines.

Knightscope’s current product lineup hinges on the performance of its K1 stationary robot, its indoor-roving K3 model and its outdoor perimeter-patrolling K5 sentry. The company’s robotic platform is designed to potentially reduce the costs of providing security while avoiding not only physical obstacles in their path, but some of the emotional limitations of human patrols as well, such as fatigue, boredom, texting and even fear or anger.

Far from the armed profile of movie industry Robocops, or even the more real-world use of National Guard forces supporting U.S. Capitol security forces in the wake of this month’s deadly incursion by domestic terrorists against Congress and ahead of the inauguration of President-elect Joe Biden (https://ibn.fm/4vFhz), Knightscope’s robotic patrols surveil property grounds without weapons but provide a deterrent to crime through their capacity to detect, record and communicate details of incidents for further investigation.  They also provide officers and guards unprecedented situational awareness.

Knightscope’s machines are in service across the country, having been deployed at numerous Fortune 1000 companies, hospitals, police departments and the Veterans Administration. Features such as 360-degree eye-level HD streaming video, speakers for live or recorded communication, face and license plate recognition, and broadcast signal reception make the robots capable of responding to a variety of scenarios during their patrols. Their thermal anomaly detection technology has also helped alert authorities to the budding possibility of a fire emergency before the situation got out of hand (https://ibn.fm/WoIYY).

During the ongoing pandemic crisis, the sentries have the added benefit of being unaffected by a viral illness.

While the autonomous robots arose out of the same philosophy propelling the transportation industry toward self-driving cars and shuttles, Knightscope CEO William Santana Li said during a recent fireside chat hosted by IPO Edge that he set aside his automotive industry background for the more market-responsive parallel venture in the realm of security to commercialize AI-driven technology (https://ibn.fm/h3iCZ).

“Depending on who you believe, over $80 billion has been invested in self-driving autonomous (automobile) technology. There are 200-plus companies working on it. How many people in the audience did a transport or moved something or moved themselves this week in an autonomous vehicle? Nobody, right? So $80 billion went into the sector, nobody shipped anything that’s commercially viable,” Li said. “I believe Knightscope is the only company in the world operating 24/7/365 across an entire nation, fully autonomous, no human intervention, with real-world clients and real-world environments.”

Li’s vision of platform development equates the self-driving car build-up to trying to travel to Pluto before learning to travel to the moon. Knightscope’s security robots are responsive to an actual societal need and represent a logical, incremental approach by the company. The company’s funding profile is backed by more than 18,000 investors (and growing) through its Reg A+ offering, with security officers of large corporations, shopping mall directors, municipal police officers and federal agents on board.

Market analysts at Mordor Intelligence foresee the global market for autonomous security robots reaching $3.59 billion by 2025, and its most recent report gives a shout-out to Knightscope’s K5 model by stating it signals significant progress in the technology, adding, “Earlier, these robots had insufficient capabilities; however, with advances in sensor technology and automation capabilities, these robots have been developed to be useful in working applications” (https://ibn.fm/7KdR6).

For more information, visit the company’s website at www.Knightscope.com.

Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO.

DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Knightscope, Inc. | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present at NobleCon17

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it will present at the upcoming NobleCon17, scheduled for Jan. 19–20, 2021. The virtual event is Noble Capital Markets’ annual investor conference. GNPX’s presentation will include a company overview and address the company’s recent progress on planned clinical trials focusing on the treatment of non-small cell lung cancer. Genprex president and CEO Rodney Varner will deliver the presentation to participating investors. The Genprex presentation is scheduled for Tuesday, Jan. 19, at 3:45 p.m. EST.  A replay of the presentation will be available on the company’s website and in a catalog of all NobleCon17 presentations to be rebroadcast on Channelchek.

To register for the event, visit https://ibn.fm/C5HbI

To view the full press release, visit https://ibn.fm/f20bC

About Genprex Inc. 

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA(TM) (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Predictive Oncology (NASDAQ: POAI) Subsidiary Sells Media to Top Research Medical Centers

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in New York City and Boston. The announcement noted that those two sales are repeat orders and focus on culturing ovarian cancer cells with specific research goals; the company also announced an additional order that came from a private company conducting research on ovarian cancer. Experts forecast that the 3D cancer cell culture media market will grow at CAGR of approximately 11.3%, reaching $3.2 billion in sales in worldwide by 2027. According to the announcement, the reason for the significant growth is because older technologies do not generally reproduce a patient’s tumor cell populations, and immortalized cells, or cells that live forever and are altered from the original tumor, do not make good models for use in drug discovery and development. The company called the idea of replicating ovarian cancer cells outside of a patient’s body and in a laboratory well plate or culture flask remarkable. “We believe that this is the future of ovarian cancer research, which creates new possibilities to coming up with new treatments for this chronic and deadly disease,” said POAI president and CEO Dr. Carl Schwartz in the press release. “In order for us to find better drugs, we have to be able to grow the right patient cells in the right media. Building the ‘living library’ of cancer cells for drug screening and discovery is the right first step. Then we can focus on how to kill them.”

To view the full press release, visit https://ibn.fm/xizSs

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF) Announces Film Bubble Partnership, New CFO Appointment

  • Following the success of the Venue Bubble and Travel Bubble projects, Loop has partnered with Draganfly Inc. to launch the first Film Bubble for a major motion picture in January 2021
  • The film and television industry has seen a significant drop in revenue, and the Film Bubble is positioned to make sets safer with the technology provided by Draganfly
  • Effective December 11, 2020, Mark Lotz took over the position of Chief Financial Officer after the resignation of Abbey Abdiye

Loop Insights (TSX.V: MTRX) (OTCQB: RACMF), an innovative Internet of Things (“IoT”) technology company that delivers contactless solutions, including venue management, personalized engagement, and AI-driven insights, is partnering with Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8)) to launch the first “Film Bubble,” a solution designed to help keep movie sets safer and operational during the coronavirus pandemic (https://ibn.fm/tJAKt).

The Film Bubble provides another major opportunity for Loop as a spin-off of the recently successful NCAA Venue Bubble and Travel Bubble projects. According to Loop CEO Rob Anson, the Film Bubble will provide a great showcase for the company’s film industry solution as well as additional opportunities for travel, venue, and other healthcare applications Loop Insights has been working on.

The Film Bubble will be launched for a major motion picture scheduled to commence filming in January 2021. At this time, the names of the motion picture and the actors are being kept confidential until filming begins.

Under the partnership agreement, Loop Insights and Draganfly will combine technologies into Loop’s Venue Bubble solution with the ultimate goal of making the film and television industry safer to resume production, resulting in higher revenue and employment opportunities. “Film industry investors, insurance companies, unions, and guilds are all seeking this type of solution to keep workers safe and protect their investments,” Draganfly CEO Cameron Chell said.

Draganfly provides Safe Set Solutions for the global film and television production industry using ground-based technology for symptom pre-screening, elevated body temperature measurement, and social distancing display.

The Film Bubble solution comes at the right time for an industry that has reported billions in losses as a result of the coronavirus pandemic closing down movie theaters and production. In 2019, the North American box office amounted to $11.32 billion in total earnings and employed over 456 thousand people with several hundred thousand more employees in Canada and other countries worldwide (https://ibn.fm/hVmFz). This past November, AMC Theatres announced that they had seen a 91% drop in their revenues during the most recent earnings period resulting in a loss of $906 million in this quarter alone. The overall global entertainment industry is also projected to lose $160 billion of growth over the next five years (https://ibn.fm/Kr0Wj).

“The addition of Draganfly’s Safe Set Solutions to our Venue Bubble Platform creates an instant and powerful Film Bubble solution for an industry that has suffered catastrophic losses in 2020 and can’t afford to stay shut down for a minute longer,” Anson said. “We are extremely proud to have jointly delivered a solution to the film industry that will allow them to safely get their crews, actors, and supporting infrastructure back to work and generating prosperity, the ripple effects of which reverberate around the world.”

On the same day the Film Bubble partnership was made public, Loop Insights announced the appointment of a new Chief Financial Officer. The previous CFO, Abbey Abdiye, resigned from the company to pursue other career opportunities. He is replaced by Mark Lotz, who took over the position effective December 11, 2020 (https://ibn.fm/Vicrd). Lotz is a Chartered Professional Accountant with 26 years of post-qualification experience. His experience spans across a broad cross-section of industries that include SaaS, mining, manufacturing, financial service, and technology. Lotz has a Bachelor’s degree in Business Administration with a dual Economics major.

Backed by Amazon’s Partner Network, Loop has developed a line of powerful technologies that are simple to use but designed to transform industries. Fobi, an IoT device that is designed to seamlessly integrate with any existing point of sale infrastructure, collects 100% of the transactional data and sends it to the cloud. SmarTap is Loop’s Near Field Communication (“NFC”) device that enables consumers to check-in using a “tap” and their smartphone’s NFC compatibility. SmarTap offers a contactless consumer experience and connects with the cloud via LTE or WiFi to securely transmit data.

Loop Cloud is the middle ground where Fobi and SmarTap’s information meets, being stored digitally and creating a database for the company and their clients. When paired with either Loop solution, the Loop Cloud creates a way for the business to transform their edge-based legacy systems into a unified database.

For more information, visit the company’s website at www.LoopInsights.ai.

NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at https://ibn.fm/RACMF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Loop Insights Inc. RACMF | Leave a comment

MissionIRNewsBreaks – Loop Insights Inc. (TSXV: MTRX) (OTCQB: RACMF) Enters Strategic Agreement with Leading UK Pharmacy Solutions Provider

Loop Insights (TSXV: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick-and-mortar space, today announced the signing of a pilot agreement with PharmAssist Solutions to implement Loop’s analytics platform into multiple independent pharmacy affiliated locations. “Loop Insights data analytics solution is a game-changer for independent pharmacies here in the UK. PharmAssist Solutions has been integral to the success of the independent chain, and adding Loop’s ability to understand transaction details, shopping behaviors and habits, trends, and other powerful pieces of information once thought lost, will provide a massive benefit to each individual pharmacy,” Pharmassist Managing Director Amar Randhawa stated. “Understanding what products have been sold and prescribed gives these independents the ability to offer personal, relevant, and adjacent over the counter products to consumers, increasing sales, and delivering a more personal experience in-store. We are excited to be the first solutions provider in the UK market to offer this, and expect great uptake of the solution to our growing customer base.”

To view the full press release, visit https://ibn.fm/dKyis

About Loop Insights Inc.

Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network and sold through the TELUS IoT Marketplace. For more information, visit the company’s website at www.LoopInsights.ai.

NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at https://ibn.fm/RACMF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Loop Insights Inc. RACMF, MissionIRNewsBreaks | Leave a comment

SRAX Inc. (NASDAQ: SRAX) Announces Extension of BIGtoken Special Dividend

  • Company extends expiration of special dividend for one year
  • If declared, special dividend will consist of number, designation determined by company management
  • BIGtoken is first consumer-managed data marketplace where people can own, earn from their data

SRAX (NASDAQ: SRAX) will extend the expiration for its previously announced BIGtoken special dividend right for one year. The dividend right was set to expire on or before 5 p.m. on Dec. 31, 2020, and that deadline has been extended to on or before 5 p.m. ET on Dec. 31, 2021 (https://ibn.fm/sCKWJ).

The original dividend right was issued on Sept. 17, 2018, when SRAX, then called Social Reality Inc., announced a nontransferable right to receive at no charge a special dividend to holders of the company’s Class A common stock; the right was also extended to certain holders of the company’s common stock equivalents.

The extension announcement notes that “if and when declared, the Special Dividend will consist of such number and designation of the SRAX subsidiary BIGtoken Inc.’s securities as determined by the company’s management at their sole discretion. . . . The Special Dividend will be an analog security, i.e., not digital, and not a cryptocurrency, and the Special Dividend is expected to be a fractional non-voting security that, if and when issued, is expected to only participate in a portion of the financial performance of the BIGtoken platform.”

Initially launched by SRAX and then spun off as a separate company, BIGtoken, or BIG, is a secure consumer data-management and distribution system —the first consumer-managed data marketplace where people can own and earn from their data (https://ibn.fm/nr4Sm). Through a transparent platform and consumer reward systems, BIG offers consumers choice, transparency, and compensation for their data. Participants earn rewards, and developers are able to build pro-consumer online experiences on top of the BIG platform (https://ibn.fm/gXpcG).

At last count, BIGtoken has compensated more than 16 million users for access to their data while creating data sets across 25,000 unique market segments. Brands are offered access to this verified, opted-in data for a fee.

“BIGtoken is a secure platform that empowers you to realize and claim the value of your digital self,” the website observes (https://ibn.fm/B0Cj3). “You have a right to privacy, awareness, and choice when it comes to the data you put out into the digital world. With BIG, you can own and earn from that data while staying connected to your community.”

SRAX is currently focused on unlocking data and insights through its software-as-a-service (SaaS) platform, Sequire. Launched as a standalone platform in early 2020, Sequire now has more than 1 million investors and traders, with an estimated 91 publicly listed companies as subscribers. The explosion in growth is driven by Sequire’s extensive range of services and as companies have increasingly sought to adopt digital technology and the data generated from such mediums as a way of improving their engagement with customers and stakeholders alike.

For more information about SRAX and Sequire, visit the companies’ websites at www.SRAX.com and www.MySequire.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in SRAX, Inc. SRAX | Leave a comment

MissionIRNewsBreaks – Knightscope Inc. Secures Grocery Contract

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous security robots (“ASRs”), announced that it has entered into a contract to deploy in a national grocery chain. According to the California Grocers Association, shoplifting and organized retail crime have been on the rise, amounting to significant losses and threatening the safety of employees and customers. Knightscope’s solution will assist to reduce the burden on retailers. This will be Knightscope’s first deployment at a major grocery store and, if history repeats itself, it suspects that other similar retailers will be looking at the results for possible inclusion in their future security programs.

To view the full update, visit https://ibn.fm/nPXeY

About Knightscope

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots (“ASRs”) that deter, detect and report. The company’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Knightscope, Inc. | Leave a comment

MissionIRNewsBreaks – The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) to Launch Alkaline88(R) Products at 99 Cents Only Stores

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced that its three-liter offering and four A88-Infused(TM) flavored waters will be available in all 99 Cents Only Stores locations across California and the Southwest regions. “We are pleased to announce that our flagship brand and four of our popular flavors will be offered by another exciting banner in the specialty discount retail channel,” stated Ricky Wright, president and CEO of The Alkaline Water Company. “As a trusted national brand, it is encouraging to see our brand extension strategy in play, with our new and innovative offerings creating larger opportunities for our team. During calendar 2020, our efforts to penetrate this space have yielded strong results. Our small and large formats are now carried in approximately 8,000 stores in this channel, with a strong sales pipeline for the current year. The specialty discount channel presents a tremendous opportunity for our growing lifestyle brands, and we expect to add another 6,000 to 8,000 new store locations over the next 12-18 months. Our earlier wins in this channel are seeing good momentum with consistent repeat orders and strong turns. Beyond our beverage brands, we believe that our A88CBD products will do exceptionally well in this channel, especially as the CBD regulatory framework is further defined in 2021.”

To view the full press release, visit https://ibn.fm/LCCIp

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER  

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, The Alkaline Water Company Inc. WTER | Leave a comment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with New Berubicin Clinical Trials, Determined to Help Address Unmet Needs of GBM Patients

  • IND approval from the FDA has given CNS Pharmaceuticals the green light needed to continue with clinical research of Berubicin in patients suffering from GBM and other brain/nervous system cancers
  • Company holds the exclusive worldwide license for Berubicin, the first anthracycline to cross the blood-brain barrier in the adult brain
  • The GBM therapeutics market is expected to increase to an estimated $3.3 billion in 2024
  • CNS Pharmaceuticals’ sublicensee will be conducting the first pediatric study using Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical-stage biotechnology company that is currently specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, including the use of Berubicin for patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently working on the development and clinical trials of Berubicin for GBM and the potential of addressing other central nervous system malignancies.

Berubicin appears to be the first anthracycline to cross the blood-brain barrier in the adult brain. Its development started over 15 years ago when Reata Pharmaceuticals, Inc. (NASDAQ: RETA) conducted the first Phase I trial, creating limited clinical data. Phase I trial results indicated that 44 percent of participants reported a significant improvement in the size of the tumor. The evidence concluded that there was a positive enough impact that CNS has continued with the development and the clinical-stage trials for the drug.

CNS holds the exclusive license for Berubicin worldwide. The company goes into the year 2021 determined to move forward with the development and distribution of Berubicin for GBM. The recent approval of the United States Food and Drug Administration (“FDA”) of Berubicin as an investigational new drug (“IND”) has only increased the opportunity for CNS to move forward with the three clinical trials currently in development.

“The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase II trial in the U.S., and two trials planned by our sublicensee WPD in Poland,” CNS Pharmaceuticals CEO John Climaco said during a recent virtual presentation discussing the FDA IND approval and future company plans (https://ibn.fm/TP3oE).

The company’s sublicensee WPD Pharmaceuticals (CSE: WBIO) (FSE: 8SV1) will be conducting a Phase II trial in adults, as well as the first-ever Phase I trial in children who suffer from GBM and other cancers of the brain and central nervous system. This is the first pediatric trial of its kind.

According to Climaco, CNS aims to address the significant unmet medical need of GBM patients since the current treatment paradigm for the condition yields bleak results, and this aggressive and, as yet, incurable form of brain cancer continues to claim high mortality rates. “We have a tremendous opportunity ahead of us as we continue our mission to improve patient outcomes for GBM and build on the promising results demonstrated by Berubicin in its Phase 1 clinical trial,” he added.

The GBM treatments market is anticipated to increase to an estimated $3.3 billion in 2014, marking a CAGR of 17.4% from 2014, when the market was $659. The growth is expected to be driven by seven major markets – the United States, Spain, the UK, France, Italy, Japan, and Germany, and is the direct result of the growing unmet needs of the current market (https://ibn.fm/ZAYjM).

Berubicin is currently being produced in two labs as a result of a dual-track manufacturing strategy implemented by CNS. To ensure that current conditions do not hinder the progress of Berubicin’s development and availability, CNS has turned to United States-based Pharmaceuticals International Inc. and Italy-based BSP Pharmaceuticals SpA for the production of Berubicin for the clinical trials. Both pharmaceutical companies have diversified the supply chain, and increased the availability of Berubicin, mitigating the risks of COVID-19 in clinical trial strategies.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment